Stefanie Deinhardt-Emmer, Benjamin G Chousterman, Joerg C Schefold, Stefanie B Flohé, Tomasz Skirecki, Matthijs Kox, Martin S Winkler, Andrea Cossarizza, W Joost Wiersinga, Tom van der Poll, Markus A Weigand, Sara Cajander, Evangelos J Giamarellos-Bourboulis, Gunnar Lachmann, Massimo Girardis, Brendon P Scicluna, Ricard Ferrer, Didier Payen, Sebastian Weis, Antoni Torres, Hjalmar R Bouma
{"title":"免疫功能低下患者的败血症:诊断挑战和未来治疗","authors":"Stefanie Deinhardt-Emmer, Benjamin G Chousterman, Joerg C Schefold, Stefanie B Flohé, Tomasz Skirecki, Matthijs Kox, Martin S Winkler, Andrea Cossarizza, W Joost Wiersinga, Tom van der Poll, Markus A Weigand, Sara Cajander, Evangelos J Giamarellos-Bourboulis, Gunnar Lachmann, Massimo Girardis, Brendon P Scicluna, Ricard Ferrer, Didier Payen, Sebastian Weis, Antoni Torres, Hjalmar R Bouma","doi":"10.1016/s2213-2600(25)00124-9","DOIUrl":null,"url":null,"abstract":"Sepsis is a life-threatening, dysregulated host response to infection. Immunosuppression is a risk factor for infections and sepsis. However, the specific immune derangements elevating the risk for infections and sepsis remain unclear in the individual patient, raising the question of whether a general state of immunosuppression exists. In this Review, we explore the relationship between immunosuppression and sepsis, detailing the definitions, causes, and clinical implications. We address the effect of primary immunodeficiencies, acquired conditions, and drugs on the risk of infection and the development of sepsis. Patients with sepsis who are immunocompromised often present with atypical symptoms and diagnostic test results can differ, making early recognition difficult. Future perspectives entail novel biomarkers to improve early sepsis detection and tailored treatments to modulate immune function. Including patients who are immunocompromised in clinical trials is crucial to enhance the relevance of research findings and improve treatment strategies for this vulnerable population.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"27 1","pages":""},"PeriodicalIF":38.7000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies\",\"authors\":\"Stefanie Deinhardt-Emmer, Benjamin G Chousterman, Joerg C Schefold, Stefanie B Flohé, Tomasz Skirecki, Matthijs Kox, Martin S Winkler, Andrea Cossarizza, W Joost Wiersinga, Tom van der Poll, Markus A Weigand, Sara Cajander, Evangelos J Giamarellos-Bourboulis, Gunnar Lachmann, Massimo Girardis, Brendon P Scicluna, Ricard Ferrer, Didier Payen, Sebastian Weis, Antoni Torres, Hjalmar R Bouma\",\"doi\":\"10.1016/s2213-2600(25)00124-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sepsis is a life-threatening, dysregulated host response to infection. Immunosuppression is a risk factor for infections and sepsis. However, the specific immune derangements elevating the risk for infections and sepsis remain unclear in the individual patient, raising the question of whether a general state of immunosuppression exists. In this Review, we explore the relationship between immunosuppression and sepsis, detailing the definitions, causes, and clinical implications. We address the effect of primary immunodeficiencies, acquired conditions, and drugs on the risk of infection and the development of sepsis. Patients with sepsis who are immunocompromised often present with atypical symptoms and diagnostic test results can differ, making early recognition difficult. Future perspectives entail novel biomarkers to improve early sepsis detection and tailored treatments to modulate immune function. Including patients who are immunocompromised in clinical trials is crucial to enhance the relevance of research findings and improve treatment strategies for this vulnerable population.\",\"PeriodicalId\":51307,\"journal\":{\"name\":\"Lancet Respiratory Medicine\",\"volume\":\"27 1\",\"pages\":\"\"},\"PeriodicalIF\":38.7000,\"publicationDate\":\"2025-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Respiratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2213-2600(25)00124-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(25)00124-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
Sepsis in patients who are immunocompromised: diagnostic challenges and future therapies
Sepsis is a life-threatening, dysregulated host response to infection. Immunosuppression is a risk factor for infections and sepsis. However, the specific immune derangements elevating the risk for infections and sepsis remain unclear in the individual patient, raising the question of whether a general state of immunosuppression exists. In this Review, we explore the relationship between immunosuppression and sepsis, detailing the definitions, causes, and clinical implications. We address the effect of primary immunodeficiencies, acquired conditions, and drugs on the risk of infection and the development of sepsis. Patients with sepsis who are immunocompromised often present with atypical symptoms and diagnostic test results can differ, making early recognition difficult. Future perspectives entail novel biomarkers to improve early sepsis detection and tailored treatments to modulate immune function. Including patients who are immunocompromised in clinical trials is crucial to enhance the relevance of research findings and improve treatment strategies for this vulnerable population.
期刊介绍:
The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject.
The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.